CAR T-Cell Therapy
Chimeric Antigen Receptor (CAR) T-Cell therapy is a type of cancer treatment in which patients’ T-cells are taken from their blood and altered in a laboratory to attack cancer cells.
T-cells are a type of immune system cell. The process of CAR T-Cell therapy adds a chimeric antigen receptor (CAR) to the cell, which allows the modified T-cell to recognize and attack cancer cells. Altered T-cells are given to the patient via infusion. The team at the Joseph M. Sanzari Children’s Hospital has been certified by Novartis Pharmaceuticals to treat patients with treatment-resistant acute lymphoblastic leukemia (ALL) using the first CAR T-Cell therapy, Kymriah. It is geared toward ALL patients who have refractory disease or have relapsed.
The majority of patients who have been treated with CAR T-Cell therapy have experienced long-term remission as a result. As the only certified center to offer CAR T-Cell therapy to pediatric patients in New Jersey, the Pediatric Stem Cell Transplantation and Cellular Therapy Program at the Joseph M. Sanzari Children’s Hospital provide cutting-edge solutions that bring hope for a cure to patients for whom a cure was once thought to be impossible.